Half-Dose Photodynamic Therapy Recommended in the Management of Central Serous Chorioretinopathy during an Era of Limited Supplies of Verteporfin


First-Page Preview
Abstract of Letter to the Editor References Karasu B, Akbas YB, Aykut A, Celebi ARC. Comparison of retinochoroidal vascular and structural changes after half-dose photodynamic therapy versus half-fluence photodynamic therapy based on optical coherence tomography angiography in eyes with chronic central serous chorioretinopathy. Ophthalmologica. 2022;245(4):323–34. Liu C-F, Chen LJ, Tsai SH, Lai CC, Chan WC, Wu WC, et al. Half-dose verteporfin combined with half-fluence photodynamic therapy for chronic central serous chorioretinopathy. J Ocul Pharmacol Ther. 2014 Jun 1;30(5):400–5. Sirks MJ, van Dijk EHC, Rosenberg N, Hollak CEM, Aslanis S, Cheung CMG, et al. Clinical impact of the worldwide shortage of verteporfin (Visudyne®) on ophthalmic care. Acta Ophthalmol. 2022 Apr 6;100(7):e1522–32. van Rijssen TJ, van Dijk EHC, Yzer S, Ohno-Matsui K, Keunen JEE, Schlingemann RO, et al. Central serous chorioretinopathy: towards an evidence-based treatment guideline. Prog Retin Eye Res. 2019 Nov;73:100770. https://www.ema.europa.eu/en/documents/shortage/shortage-visudyne-verteporfin-supply-shortage_en.pdf. Article / Publication Details

Received: August 27, 2022
Accepted: December 23, 2022
Published online: January 04, 2023

Number of Print Pages: 2
Number of Figures: 0
Number of Tables: 0

ISSN: 0030-3755 (Print)
eISSN: 1423-0267 (Online)

For additional information: https://www.karger.com/OPH

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
View original article
OPHTHALMOLOGICA

Comments (0)

No login
gif
format_indent_decrease